AAPL   329.23 (+2.14%)
MSFT   185.75 (+1.55%)
FB   230.62 (+1.91%)
AMZN   2,468.73 (+0.33%)
NVDA   354.61 (+1.13%)
BABA   220.01 (+0.90%)
MU   54.21 (+5.84%)
GE   8.22 (+6.07%)
AMD   52.54 (-0.17%)
T   32.87 (+3.37%)
ACB   13.84 (-2.74%)
F   7.41 (+12.80%)
NFLX   414.24 (-0.02%)
BAC   28.41 (+6.05%)
BA   215.73 (+17.05%)
AAPL   329.23 (+2.14%)
MSFT   185.75 (+1.55%)
FB   230.62 (+1.91%)
AMZN   2,468.73 (+0.33%)
NVDA   354.61 (+1.13%)
BABA   220.01 (+0.90%)
MU   54.21 (+5.84%)
GE   8.22 (+6.07%)
AMD   52.54 (-0.17%)
T   32.87 (+3.37%)
ACB   13.84 (-2.74%)
F   7.41 (+12.80%)
NFLX   414.24 (-0.02%)
BAC   28.41 (+6.05%)
BA   215.73 (+17.05%)
AAPL   329.23 (+2.14%)
MSFT   185.75 (+1.55%)
FB   230.62 (+1.91%)
AMZN   2,468.73 (+0.33%)
NVDA   354.61 (+1.13%)
BABA   220.01 (+0.90%)
MU   54.21 (+5.84%)
GE   8.22 (+6.07%)
AMD   52.54 (-0.17%)
T   32.87 (+3.37%)
ACB   13.84 (-2.74%)
F   7.41 (+12.80%)
NFLX   414.24 (-0.02%)
BAC   28.41 (+6.05%)
BA   215.73 (+17.05%)
AAPL   329.23 (+2.14%)
MSFT   185.75 (+1.55%)
FB   230.62 (+1.91%)
AMZN   2,468.73 (+0.33%)
NVDA   354.61 (+1.13%)
BABA   220.01 (+0.90%)
MU   54.21 (+5.84%)
GE   8.22 (+6.07%)
AMD   52.54 (-0.17%)
T   32.87 (+3.37%)
ACB   13.84 (-2.74%)
F   7.41 (+12.80%)
NFLX   414.24 (-0.02%)
BAC   28.41 (+6.05%)
BA   215.73 (+17.05%)
Log in

NASDAQ:ZGNXZogenix Stock Price, Forecast & News

$30.44
+1.38 (+4.75 %)
(As of 06/5/2020 12:30 PM ET)
Add
Compare
Today's Range
$29.57
Now: $30.44
$31.38
50-Day Range
$25.38
MA: $27.90
$30.32
52-Week Range
$16.65
Now: $30.44
$57.22
Volume269,898 shs
Average Volume559,855 shs
Market Capitalization$1.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Read More
Zogenix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.65 million
Book Value$5.54 per share

Profitability

Net Income$-419,500,000.00
Net Margins-8,374.54%

Miscellaneous

Employees90
Market Cap$1.68 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

How has Zogenix's stock been impacted by COVID-19 (Coronavirus)?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZGNX stock has increased by 34.2% and is now trading at $30.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zogenix?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zogenix.

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Zogenix.

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) posted its earnings results on Tuesday, May, 5th. The company reported ($0.54) earnings per share for the quarter, topping analysts' consensus estimates of ($1.08) by $0.54. The firm had revenue of $1.25 million for the quarter, compared to the consensus estimate of $0.38 million. Zogenix had a negative return on equity of 47.19% and a negative net margin of 8,374.54%. The company's revenue was up 124800.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.83) earnings per share. View Zogenix's earnings history.

What price target have analysts set for ZGNX?

11 brokers have issued twelve-month target prices for Zogenix's stock. Their forecasts range from $27.00 to $78.00. On average, they expect Zogenix's share price to reach $57.90 in the next twelve months. This suggests a possible upside of 90.2% from the stock's current price. View analysts' price targets for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. According to Zacks Investment Research, "Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome. " (5/10/2020)
  • 2. Northland Securities analysts commented, "We note that 1504 demonstrated 63% and 54% reductions in mean monthly convulsive seizure frequency, versus comparator arms that excluded or included stiripentol therapy, respectively. FINTEPLA was also shown to significantly extend seizure free intervals to ~1 month, with an exceptionally high response rate >70%." (7/8/2019)

Has Zogenix been receiving favorable news coverage?

Headlines about ZGNX stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zogenix earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the next several days. View the latest news aboutZogenix.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FDx Advisors Inc. (12.68%), FDx Advisors Inc. (12.68%), RA Capital Management L.P. (9.53%), BlackRock Inc. (6.59%), Janus Henderson Group PLC (4.47%) and Federated Hermes Inc. (3.73%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Erle T Mast, Gail M Farfel, James B Breitmeyer, Life Sciences Maste Perceptive, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View institutional ownership trends for Zogenix.

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Pictet Asset Management Ltd., Morgan Stanley, WINTON GROUP Ltd, Ensign Peak Advisors Inc, Wells Fargo & Company MN, Two Sigma Advisers LP, and Mutual of America Capital Management LLC. Company insiders that have sold Zogenix company stock in the last year include Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, and Stephen J Farr. View insider buying and selling activity for Zogenix.

Which major investors are buying Zogenix stock?

ZGNX stock was acquired by a variety of institutional investors in the last quarter, including FDx Advisors Inc., FDx Advisors Inc., RA Capital Management L.P., Janus Henderson Group PLC, Vivo Capital LLC, Federated Hermes Inc., Eagle Asset Management Inc., and Fairmount Funds Management LLC. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, Life Sciences Maste Perceptive, and Mark C Wiggins. View insider buying and selling activity for Zogenix.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $30.44.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.68 billion and generates $3.65 million in revenue each year. The company earns $-419,500,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. Zogenix employs 90 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.